{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:41:44Z","timestamp":1782949304123,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Biologics is used for treating moderate to severe plaque psoriasis (MSPP), which represent one of the foremost therapeutic advancements in disease of dermatology. Up to now, the relative efficacy and safety across approved andinvestigational biologics for MSPP is still unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study aimed to comparative effectiveness of various biological treatments for MSPP measured by PASI75, PASI90 and PASI100 (The ratio of patients whose Psoriasis Area and Severity Index score (PASI) decreased by \u2265 75%, 90% and 100% compared with baseline, respectively). In addition, random models were used together with a Bayesian method to compare direct and indirect Adverse Events (AEs) of biologics with placebo, to make probabilistic statements and predictions on their AEs. The analytic data set was made up of summarized data from 54 trials, including 27,808 patients, with treatment of 17 biologics. Three mathematic models with nonparametric placebo evaluations were established to characterize the longitudinal direction profile for the three efficacy measures as above mentioned.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our results showed significant differences among treatments. Bimekizumab, sonelokimab, and ixekizumab were found to be the most effective treatments among the biologics. The effects of covariate were further evaluated, patients\u2019 age, body weight, duration of disease and percentage of patients previously treated with a biological therapy showed impact on the efficacy. In addition, we found that ixekizumab and risankizumab displayed relatively stable as for efficacy and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our findings provide valuable insights into the comparative effectiveness and safety of biologics for MSPP treatment. These results may aid in clinical decision-making and ultimately improve patient outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1151977","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T04:14:25Z","timestamp":1684988065000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis"],"prefix":"10.3389","volume":"14","author":[{"given":"Weiqi","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boran","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongsheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6983","article-title":"Sea Buckthorn extract in the treatment of psoriasis","volume":"17","author":"Boca","year":"2019","journal-title":"Exp Ther Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.28376","article-title":"Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab","volume":"6","author":"Aira","year":"2014","journal-title":"MAbs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2018.039","article-title":"TNF inhibitors for psoriasis","volume":"37","author":"Chima","year":"2018","journal-title":"Semin Cutan Med Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1356498","article-title":"Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis","volume":"13","author":"Jeon","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.586827","article-title":"Model-based meta-analysis in psoriasis: a quantitative comparison of biologics and small targeted molecules","volume":"12","author":"He","year":"2021","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"20406223211037846","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-24007-2","volume-title":"Modeling dose-response microarray data in early drug development experiments using r: order-restricted analysis of microarray data","author":"Lin","year":"2012"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0188-4409(00)00242-3","article-title":"Pharmacokinetic-pharmacodynamic modeling: why","volume":"31","author":"P\u00e9rez-Urizar","year":"2000","journal-title":"Arch Med Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00760-8","article-title":"Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.19.5332","article-title":"IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding","volume":"20","author":"Hymowitz","year":"2001","journal-title":"EMBO J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201505","article-title":"Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation","volume":"190","author":"Johnston","year":"2013","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-Severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14974","article-title":"Comparison of guidelines for the use of ustekinumab for psoriasis in the united states","volume":"34","author":"Chat","year":"2021","journal-title":"Europe United Kingdom: A Crit appraisal Compr Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.242","article-title":"Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond","volume":"90","author":"Mandema","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0010.3854","article-title":"Compounds of psoriasis with obesity and overweight","volume":"71","author":"Owczarczyk-Saczonek","year":"2017","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13853","article-title":"Biologic treatments for elderly patients with psoriasis","volume":"44","author":"Momose","year":"2017","journal-title":"J Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/ddg.14308","article-title":"Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis","volume":"19","author":"Xu","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/bjd.12025","article-title":"Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal","volume":"167","author":"Spuls","year":"2012","journal-title":"Br J Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2016.09.021","article-title":"Clinical efficacy and safety of ixekizumab for treatment of psoriasis","volume":"108","author":"Azevedo","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14868","article-title":"Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders","volume":"32","author":"Gooderham","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15653","article-title":"Safety of selective IL-23p19 inhibitors for the treatment of psoriasis","volume":"33","author":"Crowley","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1151977\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T04:14:29Z","timestamp":1684988069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1151977\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2023.1151977"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1151977","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"article-number":"1151977"}}